MICRAININ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MICRAININ (MICRAININ).
MICRAININ is a combination of acetaminophen (paracetamol) and butalbital. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and modulating pain perception via activation of descending serotonergic pathways. Butalbital is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing central nervous system depression.
| Metabolism | Acetaminophen is primarily metabolized in the liver via glucuronidation and sulfation; a minor pathway via CYP2E1 and CYP3A4 produces the toxic metabolite NAPQI. Butalbital is extensively metabolized by CYP2C19 and other hepatic enzymes. |
| Excretion | Primarily renal (70% unchanged, 20% as sulfate conjugate); biliary/fecal <10% |
| Half-life | Terminal elimination half-life 8-12 hours; in elderly or severe renal impairment, may extend to 24 hours |
| Protein binding | 70-80% bound to albumin |
| Volume of Distribution | 0.3-0.5 L/kg; indicates moderate distribution into total body water |
| Bioavailability | Oral: 60-70% (due to first-pass metabolism); Intramuscular: 75-85%; Intravenous: 100% |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-10 minutes; Intramuscular: 15-30 minutes |
| Duration of Action | 4-6 hours; may be prolonged in hepatic or renal impairment (up to 8-12 hours) |
| Molecular Weight | 218.25 Da |
2 tablets orally at onset of migraine, then 1 tablet every 1-2 hours as needed, up to 4 tablets per attack, not to exceed 6 tablets per day. Each tablet contains isometheptene mucate 65 mg, dichloralphenazone 100 mg, and acetaminophen 325 mg.
| Dosage form | TABLET |
| Renal impairment | Not studied; use caution with CrCl <30 mL/min. Avoid if severe renal impairment (CrCl <15 mL/min) due to acetaminophen and dichloralphenazone accumulation. No specific dose adjustment guidelines available. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh C). In moderate impairment (Child-Pugh B), reduce dose by 50% or increase dosing interval. In mild impairment (Child-Pugh A), no adjustment necessary but monitor. |
| Pediatric use | Not recommended for pediatric patients due to lack of safety and efficacy data; alternative agents preferred. |
| Geriatric use | Use with caution due to increased sensitivity to anticholinergic effects, sedation, and hepatotoxicity. Initiate at lower doses (e.g., 1 tablet at onset) and titrate slowly. Monitor renal and hepatic function. |
| 1st trimester | Contraindicated in first trimester due to risk of fetal hydantoin syndrome and other congenital anomalies (e.g., cleft palate, cardiac defects). |
| 2nd trimester | Contraindicated in second trimester due to ongoing risk of congenital anomalies and potential for impaired fetal growth. |
| 3rd trimester | Contraindicated in third trimester due to risk of neonatal hemorrhage, withdrawal syndrome, and coagulopathy. |
Clinical note
Comprehensive clinical and safety monograph for MICRAININ (MICRAININ).
| Placental transfer | Mephenytoin crosses the placenta readily, achieving fetal serum concentrations similar to maternal levels. |
| Breastfeeding | Mephenytoin is excreted into breast milk in low concentrations; however, due to potential for adverse effects (e.g., sedation, poor sucking, methemoglobinemia) in the nursing infant, breastfeeding is generally not recommended. If used, monitor infant for signs of toxicity. |
■ FDA Black Box Warning
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
| Serious Effects |
History of hypersensitivity to hydantoinsPregnancy (all trimesters)Severe hepatic impairmentPorphyria
| Precautions | Hepatotoxicity: Severe liver injury may occur with acetaminophen, especially with chronic use or doses >4000 mg/day. Monitor liver function. Dependence: Butalbital can cause tolerance and dependence; withdrawal symptoms may occur upon abrupt discontinuation. CNS depression: May impair mental and physical abilities; caution with alcohol or other CNS depressants. Renal impairment: Use with caution in patients with severe renal disease. |
| Food/Dietary | Avoid excessive caffeine intake from coffee, tea, soda, or chocolate as it may increase caffeine-related side effects. Grapefruit juice may potentiate effects; limit consumption. Alcohol increases risk of drowsiness and hepatotoxicity. |
Loading safety data…
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | MICRAININ is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate; barbiturates are associated with increased risk of congenital malformations, particularly neural tube defects, when used in the first trimester. Chronic use in the third trimester can lead to neonatal withdrawal syndrome and floppy infant syndrome. Acetaminophen is generally considered low risk at therapeutic doses. Caffeine in moderate amounts is not strongly associated with major malformations, but high doses may increase risk of miscarriage. |
| Fetal Monitoring | Monitor fetal growth and development via ultrasound during pregnancy. Assess for signs of neonatal withdrawal after delivery. Monitor maternal liver function if acetaminophen use is prolonged or high dose. Monitor for maternal sedation, hypotension, and respiratory depression. |
| Fertility Effects | No specific data on MICRAININ effects on fertility. However, caffeine may negatively impact female fertility at high doses. Butalbital may affect hormonal balance due to enzyme induction, but clinical significance is unclear. |
| Clinical Pearls | MICRAININ is a fixed-dose combination of butalbital, acetaminophen, and caffeine, used for tension-type headache. Butalbital is a barbiturate with abuse potential; limit quantity prescribed. Acetaminophen hepatotoxicity risk with >3000 mg/day. Caffeine may exacerbate anxiety or insomnia. Avoid in porphyria, severe hepatic impairment, or history of substance abuse. Contraindicated with MAOIs. |
| Patient Advice | Take exactly as prescribed; do not increase dose or frequency. · Avoid alcohol while taking this medication. · Do not exceed 4000 mg acetaminophen per day from all sources. · This medication can be habit-forming; do not share with others. · May cause drowsiness; avoid driving or operating machinery until you know how it affects you. · Report signs of liver injury: yellowing skin/eyes, dark urine, abdominal pain. · Do not use for more than 5 days per week to avoid rebound headaches. |